Randomized Trialhigh evidence
Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.
Circulation·March 11, 2025·PMID 39556714
Why it mattersThis is the first trial to show that a GIP/GLP-1 receptor agonist comprehensively improves clinical outcomes, functional status, and patient-reported measures in HFpEF with obesity, addressing a high-unmet-need population.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled